OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) shares were up 1.7% during trading on Friday . The company traded as high as $12.54 and last traded at $12.45, with a volume of 88,187 shares trading hands. The stock had previously closed at $12.24.

A number of research analysts have recently commented on OMED shares. Mizuho lifted their price objective on shares of OncoMed Pharmaceuticals from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, May 26th. Jefferies Group reissued a “buy” rating on shares of OncoMed Pharmaceuticals in a research report on Sunday, May 22nd. Cantor Fitzgerald reissued a “buy” rating on shares of OncoMed Pharmaceuticals in a research report on Wednesday, June 8th. Zacks Investment Research downgraded shares of OncoMed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 10th. Finally, Leerink Swann raised their target price on shares of OncoMed Pharmaceuticals from $11.00 to $13.00 and gave the stock a “market perform” rating in a research note on Thursday, May 5th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $19.14.

The firm has a 50 day moving average of $12.80 and a 200 day moving average of $12.29. The firm’s market capitalization is $378.73 million.

OncoMed Pharmaceuticals (NASDAQ:OMED) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by $0.17. During the same quarter last year, the firm posted ($0.49) EPS. The business had revenue of $6.40 million for the quarter, compared to analysts’ expectations of $8.28 million. The company’s revenue was down 34.0% on a year-over-year basis. On average, equities analysts expect that OncoMed Pharmaceuticals Inc. will post ($3.29) earnings per share for the current fiscal year.

An institutional investor recently bought a new position in OncoMed Pharmaceuticals stock. Jennison Associates LLC bought a new stake in OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) during the fourth quarter, according to its most recent filing with the SEC. The institutional investor bought 89,546 shares of the biopharmaceutical company’s stock, valued at approximately $2,018,000. Jennison Associates LLC owned 0.30% of OncoMed Pharmaceuticals at the end of the most recent quarter.

OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.